Related Experiment Videos
Effects of aspirin on status of thrombin generation in atrial fibrillation
K Yamamoto1, U Ikeda, H Fukazawa
1Department of Cardiology, Jichi Medical School, Tochigi, Japan.
The American Journal of Cardiology
|March 1, 1996
Insights
Aspirin (acetylsalicylic acid) reduced platelet aggregation but not coagulation in atrial fibrillation patients. Anticoagulant therapy is recommended over aspirin for preventing embolism in this population.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Atrial fibrillation increases the risk of systemic embolism due to altered hemostasis.
- Antiplatelet and anticoagulant therapies are used for stroke prevention in atrial fibrillation.
Purpose of the Study:
- To evaluate the effects of aspirin on platelet function and coagulation in patients with atrial fibrillation.
- To compare the efficacy of aspirin versus anticoagulant therapy for embolism prevention.
Main Methods:
- Patients with atrial fibrillation received aspirin 330 mg/day.
- Platelet function and coagulation activity were assessed.
Main Results:
- Aspirin significantly suppressed platelet function.
- Aspirin did not alter the elevated coagulation activity observed in these patients.
- Findings suggest a differential effect on hemostatic pathways.
Conclusions:
- Anticoagulant therapy is more appropriate than aspirin for preventing systemic embolism in atrial fibrillation.
- Targeting coagulation may be more effective than solely inhibiting platelets.
Abstract:
Aspirin 330/mg/day suppressed platelet function in patients with atrial fibrillation, although it did not affect the increased coagulation activity in these patients. Findings support the premise that anticoagulant therapy is more appropriate than aspirin for the prevention of systemic embolism in patients with atrial fibrillation.